Harvard Bioscience, Inc. (NASDAQ:HBIO) CEO Jeffrey Duchemin sold 87,022 shares of Harvard Bioscience stock in a transaction on Friday, March 9th. The stock was sold at an average price of $4.53, for a total value of $394,209.66. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Harvard Bioscience, Inc. (HBIO) opened at $4.80 on Tuesday. Harvard Bioscience, Inc. has a fifty-two week low of $2.25 and a fifty-two week high of $5.20. The company has a current ratio of 3.40, a quick ratio of 1.87 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $160.45, a price-to-earnings ratio of 76.67 and a beta of 1.32.
Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings results on Thursday, March 1st. The medical instruments supplier reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05. Harvard Bioscience had a positive return on equity of 2.38% and a negative net margin of 0.85%. The business had revenue of $27.46 million for the quarter, compared to analyst estimates of $26.60 million. research analysts expect that Harvard Bioscience, Inc. will post 0.11 earnings per share for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of HBIO. Granahan Investment Management Inc. MA raised its holdings in Harvard Bioscience by 80.7% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 537,467 shares of the medical instruments supplier’s stock valued at $2,016,000 after buying an additional 240,055 shares during the period. New York State Common Retirement Fund purchased a new stake in Harvard Bioscience in the 3rd quarter valued at about $321,000. Dimensional Fund Advisors LP raised its holdings in Harvard Bioscience by 4.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,710,722 shares of the medical instruments supplier’s stock valued at $4,362,000 after buying an additional 79,374 shares during the period. Segall Bryant & Hamill LLC raised its holdings in Harvard Bioscience by 9.8% in the 4th quarter. Segall Bryant & Hamill LLC now owns 836,318 shares of the medical instruments supplier’s stock valued at $2,760,000 after buying an additional 74,307 shares during the period. Finally, Algert Global LLC raised its holdings in Harvard Bioscience by 25.7% in the 4th quarter. Algert Global LLC now owns 187,422 shares of the medical instruments supplier’s stock valued at $618,000 after buying an additional 38,328 shares during the period. Hedge funds and other institutional investors own 63.54% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3258927/insider-selling-harvard-bioscience-inc-hbio-ceo-sells-87022-shares-of-stock.html.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.